219832-49-2

MP-A08 is an ATP-competitive inhibitor of sphingosine kinases SPHK1 and SPHK2 (K_is = 27 and 6.9 μM, respectively). It is selective for SPHK1/2 over a panel of 140 human protein kinases at concentrations up to 25 μM. MP-A08 (15 μM) reduces generation of cellular sphingosine-1-phosphate (S1P; ) without inducing degradation of SPHK1 in Jurkat cells. It induces a 3.7-, 3.5-, and 5.8-fold increase in C-18 ceramide , C-20 ceramide , and C20:1-ceramide levels, respectively, and dose-dependently activates the apoptosis-associated p38 and JNK pathways in vitro. MP-A08 reduces proliferation of a variety of human cancer cell lines (EC₅₀s = 8-44.9 μM). MP-A08 also reduces tumor vasculature, as determined by CD31 staining, and volume as well as S1P protein levels in A549 human lung adenocarcinoma xenografts in mice.

NSC 122314 is selective ATP competitive sphingosine kinase 2 and 1 inhibitor. Also it induces mitochondrial-associated apoptosis.

ChEBI: MP-A08 is a sulfonamide that consists of two moieties of 4-methyl-N-phenylbenzenesulfonamide connected to each other at position 2 by an aldimine linker. It is a ATP-competitive inhibitor of sphingosine kinase that targets both SK1 and SK2 (Ki values of 27 muM and 6.9 muM, respectively) and exhibits anti-cancer properties. It has a role as an antineoplastic agent, an apoptosis inducer, an angiogenesis inhibitor and an EC 2.7.1.91 (sphingosine kinase) inhibitor. It is a sulfonamide, a member of toluenes and an aldimine.

SphK1

Store at -20°C

[1] MELISSA R PITMAN. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.[J]. Oncotarget, 2015: 7065-7083. DOI: 10.18632/oncotarget.3178